pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›CTx-001
drug · gene
save

CTx-001

Phase 2updated 6mo ago
by Complement Therapeutics Ltd🔗 ChEMBL
Phase 2
community read0 votes

Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

indications

indications
AMD

targets

B-cell lymphoma/leukemia 11A

all catalysts(0)

nothing on the calendar yet

Trials studying CTx-001

  • phase2An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemianot yet recruitingn=143

News(10)

  • Cellectis may cut 70% of workforce
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 2h ago
  • Beam’s base editing therapy for sickle cell hits goal in pivotal trial
    The result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.
    biopharma_dive · 5d ago
  • Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
    Gearing up for a potential FDA filing by the end of the year, Beam Therapeutics revealed results from a phase 1/2 study of its base-edited cell therapy risto-cel, showing the potential sickle cell…
    fiercebiotech · 5d ago
  • Vertex, ahead of FDA decision, calms fears surrounding kidney drug
    On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
    biopharma_dive · 12d ago
  • Plug-and-play gene therapy: FDA executes on vision that’s been in the works for years
    Former biologics boss Peter Marks had a vision. With the FDA’s latest draft guidance, it’s coming to fruition. Speaking with BioSpace, current CBER leader Karim Mikhail said the “adapted pathway” i…
    biospace · 13d ago
  • New FDA draft guidance doubles down on expediting approvals of personalized gene therapies
    The FDA has outlined a process for allowing a single application to cover multiple variants of a gene therapy. At the same time, the Centers for Medicare & Medicaid Services has revealed plans to e…
    biospace · 18d ago
  • Most new drugs are still too costly at launch, ICER says
    A new analysis from the non-profit group found that net launch prices for new medicines spiked significantly between 2022 and 2025, and the majority were well above its cost-effectiveness guidelines.
    biopharma_dive · 26d ago
  • Biotech startup funding gap widens despite rebound in VC investment
    Though funding totals represented the highest first-half sum since the start of 2022, industry watchers are concerned that small startups are being left behind.
    biopharma_dive · 4mo ago
  • Vertex's sickle cell therapy approved for kids; United Therapeutics buys startup
    🧬 Vertex’s sickle cell gene therapy approved for kids: Casgevy may now be used to treat either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia patie…
    endpoints · 4mo ago
  • FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
    The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either sickle cell disease (SCD) with recu…
    fda_press · 4mo ago
view all news mentions →
trade names
Casgevy
MOA
B-cell lymphoma/leukemia 11A gene editing negative modulator
indication
Geographic Atrophy
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 28m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?